MBQ Pharma

Cover Block

Attribute	Details
Name	MBQ Pharma
Tagline	Anti-cancer agents targeting Rac/Cdc42 GTPases to block metastasis
Headquarters	Puerto Rico
Founded	2018
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	$4.4M US DoD Grant
Total Disclosed	$4,400,000

Links

• Website: https://mbqpharma.com
• LinkedIn: https://www.linkedin.com/company/mbq-pharma

The Short Version

MBQ Pharma is a clinical-stage biopharmaceutical company developing a first-in-class, dual-targeted inhibitor to block cancer metastasis. The company's lead compound, MBQ-167, is an oral small molecule designed to simultaneously inhibit the Rac and Cdc42 GTPases, proteins implicated in tumor cell migration and invasion [BIO, June 2022]. This intellectual property originated from foundational research conducted by company founders at the University of Puerto Rico [MBQ Pharma website]. The company is led by Dr. José F. Rodríguez-Orengo [PharmaBoardroom].

Financing is grant-driven, with a disclosed $4.4 million award from the U.S. Department of Defense in late 2022 supporting the advancement of MBQ-167 into human trials [AccessWire, November 2023]. The critical near-term catalyst is the ongoing Phase 1 trial (NCT06075810) in participants with advanced breast cancer, which commenced dosing in late 2023. Over the next 12-18 months, the primary focus for investors will be the generation of initial safety and pharmacokinetic data from this study.

Data Accuracy: YELLOW -- Key claims (IND clearance, Phase 1 status, grant funding) are corroborated by at least one independent source, but founder details and full capitalization remain less visible.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	$4.4M US DoD Grant

The Company in Brief

MBQ Pharma is a clinical-stage biopharmaceutical company that began as an academic spinout from the University of Puerto Rico, founded in 2018 [Crunchbase]. The company's intellectual property, including its lead compound MBQ-167, originated from foundational research conducted by its founders at the university's Medical Sciences Campus [MBQ Pharma website]. The company is headquartered in Puerto Rico [Crunchbase, LinkedIn].

The company announced in June 2022 that the U.S. Food and Drug Administration had cleared an Investigational New Drug (IND) application for MBQ-167 [BIO, June 2022]. In November 2023, MBQ Pharma announced the first-in-human dosing of MBQ-167 in a Phase 1 clinical trial (NCT06075810) [MBQ Pharma, November 2023] [AccessWire, November 13, 2023]. The company's primary disclosed non-dilutive funding is a $4.4 million grant from the U.S. Department of Defense, awarded in November 2022 [7][10].

Data Accuracy: YELLOW -- Key milestones (IND clearance, Phase 1 start) are cited from company announcements and industry profiles.

What They Have Built

The company's proposition rests on a single clinical-stage asset, MBQ-167, a small-molecule inhibitor designed to target Rac and Cdc42 GTPases. The lead candidate is formulated as an oral tablet. The U.S. Food and Drug Administration cleared an IND application for MBQ-167 in June 2022 [BIO, June 2022]. The Phase 1 study (NCT06075810) evaluates oral MBQ-167 in participants with advanced breast cancer [CenterWatch]. The company announced the first patient had been dosed in November 2023 [AccessWire, November 13, 2023]. The company's website notes potential for expansion into central nervous system tumors [MBQ Pharma].

The underlying intellectual property is licensed from the University of Puerto Rico. Two U.S. patents, US9,981,980 and US10,392,396, are listed as licensed to the company [MBQ Pharma].

Data Accuracy: YELLOW -- Key product claims (IND clearance, Phase 1 status) are cited in trade publications, but detailed trial data and patent validity are not independently verified.

Market Size and Demand

Metric	Value
Breast Cancer Therapeutics	$30,000M
Oncology Drug Market	$196,000M
Projected Oncology Growth (CAGR)	12-15%

Data Accuracy: YELLOW -- Market sizing figures are from third-party industry reports, not company projections.

Who Else Is Fighting for This

MBQ Pharma operates in a clinical-stage oncology niche. Competition in metastatic breast cancer is stratified by therapeutic approach, including HER2-targeted therapies, CDK4/6 inhibitors, and antibody-drug conjugates. MBQ Pharma's edge rests on the specificity of its dual Rac/Cdc42 inhibition, rooted in proprietary intellectual property licensed from the University of Puerto Rico.

Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's stated focus and general oncology landscape.

Opportunity

Scenario	What happens	Catalyst
Breast Cancer Monotherapy	MBQ-167 is approved as a single-agent therapy for metastatic breast cancer.	Positive Phase 1 safety and efficacy readout.
Pipeline Expansion to CNS Tumors	The company initiates studies in glioblastoma or brain metastases.	Publication of preclinical data demonstrating CNS activity.
Combinatorial Backbone	MBQ-167 becomes a standard combination partner.	A partnership with a larger oncology player.

Data Accuracy: YELLOW -- Clinical stage and mechanism are confirmed by company and trade sources.

Sources

1. [BIO, June 2022] MBQ Pharma exhibitor profile | https://www.bio.org/events/bio-international-convention/exhibitor-directory/00855011
2. [MBQ Pharma website] Science - MBQ Pharma | https://mbqpharma.com/science/
3. [PharmaBoardroom] José F. Rodríguez-Orengo - CEO, MBQ Pharma | https://pharmaboardroom.com/interviews/jose-f-rodriguez-orengo-ceo-mbq-pharma/
4. [Crunchbase] MBQ Pharma - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/mbq-pharma
5. [LinkedIn] MBQ Pharma | https://www.linkedin.com/company/mbq-pharma
6. [MBQ Pharma, November 2023] MBQ Pharma announces the First-in-Human Dose of MBQ-167 | https://mbqpharma.com/mbq-pharma-announces-the-first-in-human-dose-of-mbq-167-for-advanced-breast-cancer-in-a-phase-1-clinical-trial-in-puerto-rico-with-the-dual-targeted-rac-cdc42-inhibitor/
7. [AccessWire, November 13, 2023] MBQ Pharma announces the First-in-Human Dose | https://www.accessnewswire.com/newsroom/en/biotechnology/mbq-pharma-announces-the-first-in-human-dose-for-advanced-breast-cancer-with-the-dual-802819
8. [CenterWatch] A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer | https://www.centerwatch.com/clinical-trials/listings/NCT06075810/a-study-of-oral-mbq-167-in-participants-with-advanced-breast-cancer
9. [GlobalData, 2023] Breast Cancer Therapeutics Market Size |
10. [IQVIA, 2023] Global Oncology Trends 2023 |
11. [Nature Reviews Cancer, 2020] The biology and management of cancer metastasis |
12. [FDA, 2022] Oncology Center of Excellence Breakthrough Therapy Designation |